R Mehta

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. doi request reprint Plasminogen activator inhibitor type 1 deficiency
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Haemophilia 14:1255-60. 2008
  2. doi request reprint Plasminogen deficiency
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Haemophilia 14:1261-8. 2008
  3. ncbi request reprint An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
    Haemophilia 12:54-61. 2006

Collaborators

Detail Information

Publications3

  1. doi request reprint Plasminogen activator inhibitor type 1 deficiency
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Haemophilia 14:1255-60. 2008
    ..Because of lack of standardized commercially available PAI-1 activity assay sensitive in the lowest range, the true prevalence of this rare condition has not been established...
  2. doi request reprint Plasminogen deficiency
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Haemophilia 14:1261-8. 2008
    ..Unfortunately, no plasminogen concentrate is currently available commercially for either systemic or local therapy...
  3. ncbi request reprint An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents
    R Mehta
    Department of Clinical Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
    Haemophilia 12:54-61. 2006
    ..The historical use, clinical practice concerns, published comparative studies and methods for optimization of these two bypassing agents are reviewed...